Evidence map›Paper›PMID 29089518›Full record

ArticleNature communications2017

Diversity oriented biosynthesis via accelerated evolution of modular gene clusters.

Aleksandra Wlodek, Steve G Kendrew, Nigel J Coates, Adam Hold, Joanna Pogwizd, Steven Rudder, Lesley S Sheehan, Sarah J Higginbotham, Anna E Stanley-Smith, Tony Warneck and 22 more

Abstract read
In one paragraph

Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Late-stage diversification of bacterial natural products through biocatalysis.Frontiers in bioengineering and biotechnology · 2024
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Aleksandra WlodekIsomerase Therapeutics Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK.ORCID http://orcid.org/0000-0001-5485-9978
Steve G KendrewBiotica Technology Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK.
Nigel J CoatesIsomerase Therapeutics Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK.
Adam HoldIsomerase Therapeutics Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK.
Joanna PogwizdIsomerase Therapeutics Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK.
Steven RudderIsomerase Therapeutics Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK.
Lesley S SheehanIsomerase Therapeutics Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK.
Sarah J HigginbothamIsomerase Therapeutics Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK.
Anna E Stanley-SmithIsomerase Therapeutics Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK.
Tony WarneckBiotica Technology Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK.
Mohammad Nur-E-AlamBiotica Technology Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK.
Markus RadzomBiotica Technology Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK.
Christine J MartinBiotica Technology Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK.
Lois OvervoordeIsomerase Therapeutics Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK.
Markiyan SamborskyyDepartment of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QW, UK.ORCID http://orcid.org/0000-0002-6946-0385
Silke AltDepartment of Molecular Microbiology, John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK.
Daniel HeineDepartment of Molecular Microbiology, John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, UK.
Guy T CarterChemical and Screening Sciences, Wyeth Pharmaceuticals, 401 North Middletown Road, Pearl River, NY, 10965, USA.
Edmund I GrazianiChemical and Screening Sciences, Wyeth Pharmaceuticals, 401 North Middletown Road, Pearl River, NY, 10965, USA.
Frank E KoehnChemical and Screening Sciences, Wyeth Pharmaceuticals, 401 North Middletown Road, Pearl River, NY, 10965, USA.
Leonard McDonaldChemical and Screening Sciences, Wyeth Pharmaceuticals, 401 North Middletown Road, Pearl River, NY, 10965, USA.
Alexander AlanineRoche Innovation Center Basel, Pharmaceutical Research and Early Development (PRED), Basel, CH-4070, Switzerland.
Rosa María Rodríguez SarmientoRoche Innovation Center Basel, Pharmaceutical Research and Early Development (PRED), Basel, CH-4070, Switzerland.
Suzan Keen ChaoRoche Innovation Center Basel, Pharmaceutical Research and Early Development (PRED), Basel, CH-4070, Switzerland.
Hasane RatniRoche Innovation Center Basel, Pharmaceutical Research and Early Development (PRED), Basel, CH-4070, Switzerland.
Lucinda StewardRoche Innovation Center Basel, Pharmaceutical Research and Early Development (PRED), Basel, CH-4070, Switzerland.
Isobel H NorvilleDefence Science and Technology Laboratory, Porton Down, PO17 6AD, UK.
Mitali Sarkar-TysonDefence Science and Technology Laboratory, Porton Down, PO17 6AD, UK.
Steven J MossIsomerase Therapeutics Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK.
Peter F LeadlayDepartment of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QW, UK.
Barrie WilkinsonIsomerase Therapeutics Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK. barrie.wilkinson@jic.ac.uk.ORCID http://orcid.org/0000-0001-7646-7174
Matthew A GregoryIsomerase Therapeutics Ltd., Chesterford Research Park, Cambridge, CB10 1XL, UK. matt.gregory@isomerase.co.uk.ORCID http://orcid.org/0000-0003-4890-8977

Funding

Biotechnology and Biological Sciences Research Council BB/M012158/1Biotechnology and Biological Sciences Research Council BB/N023498/1Biotechnology and Biological Sciences Research Council BBS/E/J/000PR9790
6 · The paper itself

Abstract

Erythromycin, avermectin and rapamycin are clinically useful polyketide natural products produced on modular polyketide synthase multienzymes by an assembly-line process in which each module of enzymes in turn specifies attachment of a particular chemical unit. Although polyketide synthase encoding genes have been successfully engineered to produce novel analogues, the process can be relatively slow, inefficient, and frequently low-yielding. We now describe a method for rapidly recombining polyketide synthase gene clusters to replace, add or remove modules that, with high frequency, generates diverse and highly productive assembly lines. The method is exemplified in the rapamycin biosynthetic gene cluster where, in a single experiment, multiple strains were isolated producing new members of a rapamycin-related family of polyketides. The process mimics, but significantly accelerates, a plausible mechanism of natural evolution for modular polyketide synthases. Detailed sequence analysis of the recombinant genes provides unique insight into the design principles for constructing useful synthetic assembly-line multienzymes.

Indexed as

Evolution, MolecularGenetic VariationMultigene FamilyBioengineeringBiosynthetic PathwaysPolyketide SynthasesSirolimusPolyketide SynthasesSirolimus

Identifiers

PMID29089518
PMCPMC5663706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.